Home / East & Southeast Asia · South Korea / Digital health (telemedicine) · Private

Meraki Place (My Doctor)

AI-generated working estimate based on public information / opinion & commentary, not a statement of fact / corrections & rebuttals welcome / Change log / Contact

Meraki Place (My Doctor)

Lowering the barrier to care with telemedicine—but the legal framework is early and contested

C
NARRATIVE VALUE
Certainty
●○○ low
ABCDEFG

There is no confirmed −; independently verified + decide the position (C). No unreachable strike-through.= non-additive meter

As of: 2026-Q3Status: ActiveCeiling reason: No confirmed −
History2026-Q3CHistory grows each quarter

Meraki Place (My Doctor): Lowering the barrier to care with telemedicine—but the legal framework is early and contested. The letter is C; certainty is low. Unconfirmed concerns are placed under “Watching.” (As of 2026-Q3; estimate based on public information.)

Main narrative

Meraki Place (My Doctor) is a South Korean digital-health company aiming to 'lower the barrier to care' with telemedicine. Founded in Seoul in 2021, it provides online consultations and (under regulatory constraints) medication guidance and prescription linkage, and as one of Korea's first-tier Healthcare MyData providers it lets patients and doctors manage health records. Telemedicine in Korea was originally banned in principle, temporarily allowed under COVID, and, after a June 2023 pilot, finally legalized in a limited way in December 2025 (clinic-centered, requiring a prior in-person record, with drug delivery not approved). In that pilot, 4.91 million people used telemedicine, over 40% of them in medically underserved groups such as care deserts.

One person’s story (N1)

+ A single story

A +N1 (one person’s story) will be added once an independent source is confirmed.

Positive / negative effects

+ effects

  • See the N1 above for the main positive story; independently verified + will be added over time.

− effects (confirmed)

  • No confirmed −.
Watching (unconfirmed; not counted in the assessment)
  • T
  • e
  • l
  • e
  • m
  • e
  • d
  • i
  • c
  • i
  • n
  • e
  • o
  • n
  • l
  • y
  • l
  • i
  • m
  • i
  • t
  • e
  • d
  • l
  • y
  • l
  • e
  • g
  • a
  • l
  • i
  • z
  • e
  • d
  • i
  • n
  • D
  • e
  • c
  • 2
  • 0
  • 2
  • 5
  • (
  • d
  • r
  • u
  • g
  • d
  • e
  • l
  • i
  • v
  • e
  • r
  • y
  • u
  • n
  • a
  • p
  • p
  • r
  • o
  • v
  • e
  • d
  • )
  • =
  • a
  • n
  • e
  • a
  • r
  • l
  • y
  • ,
  • c
  • o
  • n
  • t
  • e
  • s
  • t
  • e
  • d
  • f
  • r
  • a
  • m
  • e
  • w
  • o
  • r
  • k
  • ;
  • 4
  • .
  • 9
  • 1
  • m
  • i
  • l
  • l
  • i
  • o
  • n
  • /
  • 4
  • 0
  • %
  • u
  • n
  • d
  • e
  • r
  • s
  • e
  • r
  • v
  • e
  • d
  • i
  • s
  • a
  • w
  • h
  • o
  • l
  • e
  • -
  • p
  • i
  • l
  • o
  • t
  • s
  • t
  • a
  • t
  • i
  • s
  • t
  • i
  • c
  • ,
  • n
  • o
  • t
  • M
  • e
  • r
  • a
  • k
  • i
  • '
  • s
  • o
  • w
  • n
  • r
  • e
  • c
  • o
  • r
  • d
  • ;
  • a
  • m
  • i
  • d
  • -
  • s
  • i
  • z
  • e
  • d
  • c
  • o
  • m
  • m
  • e
  • r
  • c
  • i
  • a
  • l
  • p
  • l
  • a
  • t
  • f
  • o
  • r
  • m
  • .
Looking ahead (not included in the assessment)
  • Framework design after limited legalization; demonstrating reach to underserved groups; ensuring against misprescription and for safety; a sustainable business model.

A second look

The intended plus is access to care for those who struggle to travel and for care-desert groups (People), meaningful given the pilot's 4.91 million and over 40% underserved. But telemedicine in Korea was only limitedly legalized at the end of 2025 with drug delivery still unapproved, so the framework is early and contested, and access improvement is a statistic for the whole pilot, not Meraki's own record. Meraki itself is a mid-sized commercial platform (about $5M raised), and the scale, durability and independent verification of benefit are still limited. The plus is real but early and limited, so C is appropriate.

Sources

KoreaTechDesk|Lawmakers Split on Korea's Telemedicine Rules|2025-09-22|🔗
ICLG / academic|Digital Health Laws and Regulations Report 2026 Korea|2026-02-27|🔗
2026|

How to read this assessment

A Independently verified +, with no confirmed −
B Leans +, with independent backing
C Mixed. A confirmed − sets the ceiling, or much is unverified
D A serious confirmed − sets the ceiling
E A serious − reaches the core of the organization
F Serious and systemic, with little redeeming +
G Only extreme cases
Out of scope An entity whose core purpose is illegal
On hold Independent evidence is scarce on both + and −
  • Reachable upper bound (ceiling): a confirmed − sets the ceiling, and independently verified + decide the position within it. + do not cancel out −.
  • The weight of evidence is not symmetric: only confirmed − are counted; the volume of disputes or allegations goes under “Watching.” + are counted from independent evidence, while an organization’s own PR is treated as “reference.”
  • Size is not value: scale is not used in the assessment. Matters that stay within money or competition—investors, shareholders, sanctions, trade secrets—are also excluded.
  • The letter (assessment) and certainty (how reliable the information is) are separate axes.

This is a translation; the Japanese version is authoritative. The assessments here are generated automatically by AI based on published criteria. The operator does not alter individual results. Because they are AI-generated they may contain errors, and they are opinion and commentary, not statements of fact. Where evidence is insufficient, the entry is marked “On hold.” Requests for correction are accepted via the form.

Terms: Narrative Value = an assessment (A–G) of the distance between the story an organization tells and its reality / Ceiling meter = a visualization of the reachable upper bound / Watching = unconfirmed matters not counted / Protected stakeholders = people, animals, nature, and future generations. | Generated by: AI | As of: 2026-Q3 | Back to top